Vildaglus 50 mg 30 tablets

Tradename:

Vildaglus

Composition:

Each tablet contains:

Vildagliptin 50 mg

Auxiliary components:

microcrystalline cellulose, anhydrous lactose, sodium carboxymethyl starch, magnesium stearate.

Properties:

Hypoglycemic agent. Vildagliptin is a representative of the class of stimulants of the islet apparatus of the pancreas; it selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Rapid and complete inhibition of DPP-4 activity (> 90%) causes an increase in both basal and food-stimulated secretion of glucagon-like peptide type 1 (GLP-I) and glucose-dependent insulinotropic polypeptide (GIP) from the intestine into the systemic circulation throughout the day.

Indications:

Type 2 diabetes mellitus: as monotherapy in combination with diet therapy and exercise; as part of a two-component combination therapy with metformin, sulfonylurea derivatives, thiazolidinedione or insulin in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs.

Method of administration and dosage:

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

The dosage regimen is set individually depending on the efficacy, tolerability and treatment regimen.

Single dose – 50 mg, daily dose – 100 mg (50 mg 2 times / day).

Contraindications:

Hypersensitivity to vildagliptin.

Precautions:

It is not recommended for use in patients with severely impaired liver function, incl. with an increase in ALT or AST activitY> 2.5 times higher than ULN.

It is not recommended for use in patients with moderate or severe renal impairment (including end-stage renal failure and the need for hemodialysis), because data on the safety of use in this category of patients are limited.

Before starting treatment, as well as regularly (once every 3 months) during the first year of treatment, it is recommended to determine the biochemical parameters of liver function. If an increased activity of aminotransferases is detected, this result should be confirmed by a second study, and then regularly determine the biochemical parameters of liver function until they are normalized. If an excess of AST or ALT activity by 3 times or more VGN is confirmed by a repeated study, then vildagliptin is recommended to be canceled.

If jaundice or other signs of liver dysfunction develops, vildagliptin therapy should be

discontinued immediately. After normalization of liver function indicators, treatment cannot be resumed.

If insulin therapy is required, vildagliptin is used only in combination with insulin.

Vildagliptin should not be used to treat type 1 diabetes or to treat

Side effects:

From the digestive system: sometimes constipation; rarely – dysfunction of the liver (including hepatitis) asymptomatic; when combined with insulin, often – nausea, flatulence, GERD.

From the side of the central nervous system: often – tremor, dizziness, headache.

From the side of metabolism: often hypoglycemia, weight gain.

Allergic reactions: rarely – angioedema (mo often when combined with ACE inhibitors).

Others: often – asthenia, peripheral edema.

Storage method:

At a temperature not higher than 30 degrees. In a dry place.

Packaging:

The cardboard box contains 1,2 or 3 blisters of 10 tablets, paper instructions